News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Enzo Biochem (ENZ) Launch of Test for Measuring Risk of Colorectal Cancer Underscores Growing Role of Molecular Diagnostics


4/10/2012 10:27:55 AM

NEW YORK--(BUSINESS WIRE)--Enzo Biochem Inc. (NYSE: ENZ) today announced the launch of the ColonSentry™ test for assessing a patient’s risk of having colorectal cancer, the first in a pipeline of new molecular diagnostic products the Company plans for the medical community.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES